GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Aclaris Therapeutics (Aclaris Therapeutics) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aclaris Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Aclaris Therapeutics  (NAS:ACRS) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Aclaris Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (Aclaris Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
ME CDNA CSTL LDDD NVTA LAB BDSX GTH BNR FONR TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
8AT:Germany
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Website
https://www.aclaristx.com
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Executives
Joseph Monahan officer: Chief Scientific Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop officer: Chief Business Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion officer: Pres and COO C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker director, officer: President and CEO 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff director PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson officer: Chief Legal Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939